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Transmissible spongiform encephalopathies are associated with an autocatalytic conversion of nor-
mal prion protein, PrPC, to a protease-resistant form, PrPres. This autocatalytic reaction can be
reproduced in vitro using a procedure called protein misfolding cyclic ampliﬁcation (PMCA). Here
we show that, unlike brain-derived PrPC, bacterially-expressed recombinant prion protein (rPrP)
is a poor substrate for PrPres ampliﬁcation in a standard PMCA reaction. The differences between
PrPC and rPrP appear to be due to the lack of the glycophosphatidylinositol anchor in the recombi-
nant protein. These ﬁndings shed a new light on prion protein conversion process and have impor-
tant implications for the efforts to generate synthetic prions for structural and biophysical studies.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.C1. Introduction
Prion diseases, or transmissible spongiform encephalopathies
(TSEs), are infectious neurodegenerative disorders that affect many
mammalian species and include scrapie in sheep, bovine spongi-
form encephalopathy in cattle, chronic wasting disease in elk and
deer, and Creutzfeldt–Jakob disease in humans [1–3]. These dis-
eases are associated with conformational conversion of the cellular
prion protein (PrPC) to a misfolded form (PrPSc). In contrast to PrPC,
which is a-helical and sensitive to proteolytic digestion, PrPSc is
rich in b-sheet structure and shows resistance to proteolytic en-
zymes, with the proteinase K (PK)-resistant core corresponding
the C-terminal 140 residues [1–3]. An increasing body of evi-
dence indicates that the infectious TSE agent is devoid of replicat-
ing nucleic acids, consisting mainly – if not solely – of PrPSc [1–3].
This highly unusual pathogen is believed to self-propagate by anchemical Societies. Published by E
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urewicz).autocatalytic mechanism involving binding to PrP and templating
its conformational conversion to the PrPSc state.
Many efforts have been made to recapitulate prion protein con-
version and prion propagation in cell-free systems. While early
studies have shown that PrPC can be converted to PK-resistant
form of prion protein (PrPres), simply by incubation with PrPSc
from TSE-affected animals [4], the yields of this reaction were very
low and no infectivity could be attributed to the newly converted
material [5]. An important recent advance was the development
of a procedure called protein misfolding cyclic ampliﬁcation
(PMCA) which, using successive rounds of incubation and sonica-
tion, is able to replicate and indeﬁnitely amplify the PrPres con-
former employing PrPC present in brain homogenate as a
substrate [6]. Remarkably, the newly generated PrPres was shown
to cause TSE disease in experimental animals [7], suggesting that it
faithfully replicates the structure of brain PrPSc. Furthermore,
PMCA-based reactions could reproduce the phenomena of species
barriers and prion strains [8,9]. Infectious prions could also be pro-
duced by PMCA employing puriﬁed PrPC as a substrate (though
only in the presence of co-puriﬁed lipids and synthetic poly(A)
RNA molecules) [10], providing strong support to the protein-only
hypothesis of prion diseases.
Despite growing importance of PMCA technology in prion re-
search, the molecular basis of these conversion reactions remains
unclear. Here, we report data pointing to an important role of the
glycophosphatidylinositol (GPI) anchor as a modulator of PrPres
ampliﬁcation in vitro by PMCA.lsevier B.V. All rights reserved.
Fig. 1. (A) Application of protein misfolding cyclic ampliﬁcation (PMCA) procedure
to recombinant Syrian hamster PrP (rShaPrP). Lanes 1 and 2: control experiment in
which PMCA procedure was performed using 10% normal hamster brain homog-
enate (NBH) in the presence of 263 K scrapie-infected hamster brain homogenate
(SBH) seed (1:100 ratio). Lanes 3–10: experiments with rShaPrP. The recombinant
protein was added to PMCA buffer containing SBH seed only (lanes 3–6) or SBH seed
plus 10% normal brain homogenate from PrP-knockout mice (PrPKO-BH) (lanes 7–
10), and the mixtures were immediately frozen (PMCA; lanes 3, 5, 7, 9) or
subjected to 24 cycles of PMCA (PMCA+; lanes 4, 6, 8, 10). An apparent lack of
ampliﬁcation of PrPres using rShaPrP as a substrate was also observed upon
increasing the number of PMCA cycles to 48 or 80. (B) Effect of rShaPrP on the
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2.1. Reagents
Phosphatidylinositol-speciﬁc phospholipase C (PI-PLC) and PK
were purchased from Sigma–Aldrich, and peptide:N-glycosidase F
(PNGase F) was from New England BioLabs. Mouse monoclonal
anti-PrP antibodies 3F4 (recognizing epitope 109–112) and 3F10
(recognizing epitope 135–150) were kindly provided by Richard
Kascsak and Yong-Sun Kim, respectively. Recombinant full-length
Syrian hamster prion protein (rShaPrP) was expressed in Esche-
richia coli and puriﬁed as described previously [11].
2.2. Preparation of brain homogenates
Ten% (w/v) homogenates of normal Syrian golden hamster and
PrP-knockout (FVB/Prnp0/0) mice brains were prepared in PMCA
buffer (PBS containing 1% Triton X-100, 0.15 M NaCl, 4 mM EDTA,
and the Complete protease inhibitor cocktail [Roche]) as described
previously [7]. Samples containing delipidated PrPC were prepared
by incubating normal hamster brain homogenate (NBH) with PI-
PLC (1 unit/mL) for 2 h at 37 C with shaking. In control experi-
ment, NBH was subjected to the same treatment using PI-PLC inac-
tivated by boiling for 1 h. For enzymatic deglycosylation, samples
were treated with PNGase F according to the manufacturer’s
instruction. Hamster brains infected with 263 K scrapie strain were
kindly provided by Richard Carp.
2.3. PMCA procedures and immunodetection of PrP
An aliquot (1 lL) of 263 K scrapie-infected hamster brain
homogenate (SBH) was mixed with 100 lL of NBH or NBH pre-
treated with active PI-PLC or heat-inactivated PI-PLC, and the sam-
ples were subjected to 48 cycles of PMCA as described previously
[7]. For serial PMCA, an aliquot of the product of previous PMCA
reaction was diluted ten times into fresh NBH, and the mixture
was again subjected to 48 cycles of PMCA. For PMCA reactions with
the recombinant prion protein (rPrP), rShaPrP substrate at various
concentrations (1–25 lg/mL) was added to PMCA buffer contain-
ing SBH (1/100 dilution) and the samples were subjected to 24,
48, or 80 cycles of PMCA. When indicated, 10% (w/v) PrP-knockout
brain homogenate was included in the reaction mixture. For com-
petition experiments, rShaPrP (2.5–25 lg/mL) was added to PMCA
mixtures containing SBH seed and NBH (1:100 ratio), and the sam-
ples were subjected to 24 cycles of PMCA.
Western blot analysis of PrP using anti-PrP antibodies (3F4
[1:10000] or 3F10 [1:5000]) was performed as described previ-
ously [12]. For the analysis of PrPres ampliﬁcation by PMCA, sam-
ples were treated with PK (50 lg/mL, 37 C, 1 h) prior to SDS–
PAGE. For slot blotting analysis, samples in SDS–PAGE sample buf-
fer were diluted 25-fold with Tris-buffered saline (TBS, pH 7.5) and
applied to nitrocellulose membrane using Bio-Dot SF microﬁltra-
tion apparatus (Bio-Rad). The membrane was then treated with
3 M guanidine HCl (10 min, room temperature), rinsed extensively
with TBS, and probed with anti-PrP 3F10 antibody (which shows
greater sensitivity in probing slot blots than 3F4 antibody).
Although it has been suggested that negatively charged nylon
membrane may be more useful for slot blotting of delipidated PrPC
[13], using our protocol we found nitrocellulose membrane to be
equally suitable.ampliﬁcation of PrPres by PMCA using PrPC present in NBH as a substrate. rShaPrP
(0–25 lg/mL) was added to PMCA buffer containing SBH seed and NBH (1:100
ratio), and the mixtures were immediately frozen (PMCA; lanes 1, 3, 5, 7, 9) or
subjected to 24 cycles of PMCA (PMCA+; lanes 2, 4, 6, 8, 10). Both in panels A and B,
the samples were treated with PK, and the blots were probed with anti-PrP 3F4
antibody. PrPSc present in SBH seed was not detectable in Western blots shown in
panels A and B, but could be visualized using longer exposure times.3. Results
The standard PMCA protocol [7] involves suspension of normal
brain homogenate (containing PrPC) in PBS containing 1% TritonX-100, 0.15 M NaCl and 4 mM EDTA. A minute quantity of PrPSc
from brain of TSE-infected animals is then added, and the mixture
is subjected to multiple rounds of cyclic ampliﬁcation by incuba-
tion and sonication. Consistent with the previous report [7], we
found that this procedure results in very efﬁcient conversion of
Syrian hamster PrPC to PK-resistant form (PrPres), with the electro-
phoretic proﬁle of newly generated PrPres faithfully replicating
that of input PrPSc (Fig. 1A, lane 2). Here we have made a system-
atic effort to adopt this PMCA protocol to bacterially-expressed
rShaPrP. To this end, we dissolved rShaPrP in the standard PMCA
buffer, added small quantity of 263 K scrapie brain homogenate
and subjected the samples to cycles of incubation and sonication.
However, these experiments consistently failed to produce mea-
surable quantities of rShaPrP-derived PrPres (Fig. 1A, lanes 3–6).
Since additional cellular cofactors may be required for PrP conver-
sion [10,14], we repeated these experiments using the PMCA buffer
supplemented with 10% brain homogenate from PrP-knockout
mice. However, also in this case no measurable conversion of
rShaPrP could be detected (Fig. 1A, lanes 7–10), even upon increas-
ing the number of PMCA cycles to 80 and using different concen-
trations of rShaPrP (1–25 lg/mL).
Next we tested whether rShaPrP can interfere with PMCA con-
version of brain-derived PrPC. Consistent with previous data [15],
we found that the recombinant protein has a strong inhibitory ef-
fect, essentially completely blocking formation of PrPres at concen-
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PrPC) (Fig. 1B). Thus, rPrP appears to be recognized by PrPSc, com-
peting for the same binding sites with brain-derived PrPC. How-
ever, unlike PrPC, it appears to lack the ability to propagate the
structure of the PrPSc template.
The apparent inability of rShaPrP to convert to PrPres under
standard PMCA conditions is both unexpected and intriguing, espe-
cially since tertiary and secondary structures of rPrP appear to be
identical to those of brain-derived PrPC [16]. An important differ-
ence between these two proteins, however, is the lack of N-glyco-
sylation and the GPI anchor in bacterially-expressed rPrP. The ﬁrst
of these factors appears to have little effect on PrP conversion
in vitro, as indicated by recent data showing that unglycosylated
PrPC (obtained by treatment of brain PrPC with PNGase F) can be
used as a substrate in PMCA reactions to produce infectious,
PrPres-containing prions [17]. On the other hand, the role of the
GPI anchor in these conversion reactions has not yet been
explored.
To assess the importance of GPI anchor in PrPres formation
in vitro by PMCA we have prepared NBH pretreated with PI-PLC.
As shown in Fig. 2A, treatment with this enzyme results in a some-
what slower migration of PrPC during electrophoresis, indicating
the removal of GPI anchor. This effect is best evident when electro-
phoretic proﬁles are compared using proteins that have been
deglycosylated by PNGase F treatment (Fig. 2A, lanes 4–6). The
abnormal electrophoretic behavior of delipidated PrPC (i.e., slower
rather than faster migration when compared with the GPI anchor-
containing protein) is consistent with previous reports [13,18]. No
such shift in electrophoretic proﬁle was observed in control sam-
ples treated with PI-PLC that had been inactivated by heating at
100 C (Fig. 2A, lanes 2 and 5).
Intriguingly, the electrophoretic band corresponding to PI-PLC-
treated sample was much less intense, corresponding to 25–30%
of that in non-treated samples. This effect was consistently ob-
served regardless whether Western blots were probed with 3F4
or 3F10 antibody. Such an apparent ‘loss’ of band intensity in Wes-
tern blots upon PrPC treatment with PI-PLC was noted previously
and attributed to differences in the efﬁciency of transfer and/or
binding to nitrocellulose membrane between GPI anchor-contain-Fig. 2. Removal of the GPI anchor from PrPC by PI-PLC treatment. (A) Western blot
analysis of NBH preincubated in PMCA buffer alone (lane 1) and after treatment
with heat-inactivated PI-PLC (lane 2) or active PI-PLC (lane 3). Lanes 4–6 show
Western blot of the same samples after deglycosylation with peptide:N-glycosidase
F (PNGase F). The blots were probed with anti-PrP 3F4 antibody. The concentration
of PI-PLC was 1 unit/mL, and the samples were incubated with the enzyme for 2 h at
37 C with constant shaking. (B) Slot blot analysis of NBH preincubated in PMCA
buffer (lane 1) and after treatment with heat-inactivated PI-PLC (lane 2) or active
PI-PLC (lane 3). The blot was probed with anti-PrP 3F10 antibody.ing and delipidated PrPC [13]. As this effect could interfere with
our assessment of the efﬁciency of PrPres formation by PMCA
(see below), the samples used for Western blotting were reana-
lyzed by slot blotting, a technique that does not include the trans-
fer step. As shown in Fig. 2B, in this case there was no difference in
the intensity of bands corresponding to PI-PLC-treated and un-
treated PrPC. Thus, using our protocol slot blotting is better suited
for quantitative comparison of samples containing native and del-
ipidated PrPC.
In contrast to robust PrPSc-templated PMCA conversion of na-
tive PrPC to PrPres, no ampliﬁcation of PrPres could be detected
by Western blotting when PrPC without the GPI anchor (i.e. pre-
treated with active PI-PLC) was used as a substrate (Fig. 3A). To
verify that this was not due to poor detection of delipidated PrPC
in Western blotting analysis as discussed above, the presence of
PK-resistant form of PrP in PMCA-derived samples was further
tested by slot blotting. As shown in Fig. 3B, also using thisFig. 3. Ampliﬁcation of PrPres by PMCA using as a substrate PrPC present in NBH
before and after removal of the GPI moiety. (A) Western blot analysis of PrPres
ampliﬁcation. NBH pretreated with PMCA buffer (lanes 3 and 4), heat-inactivated
PI-PLC (lanes 5 and 6), or active PI-PLC (lanes 7 and 8) was mixed with SBH seed. In
a control experiment, NBH was used in the absence of SBH seed (lanes 1 and 2). The
samples were immediately frozen (PMCA; lanes 1, 3, 5 and 7) or subjected to 48
cycles of PMCA reaction (PMCA+; lanes 2, 4, 6 and 8). (B) Slot blot analysis of PrPres
ampliﬁcation. The PMCA samples described in panel A were subjected to slot
blotting before (PK) and after PK treatment (PK+), and the blots were probed with
anti-PrP 3F10 antibody. (C) Serial PMCA analysis of PrPres ampliﬁcation. Aliquots
from ﬁrst round PMCA reaction (see panel A) were diluted 10-fold into NBH (lanes
1–6) or PI-PLC-treated NBH (lanes 7–9) and subjected to 48 cycles of PMCA reaction
(second round). This procedure was repeated two more times (third and fourth
rounds). Samples used for Western blotting (panels A and C) were treated with PK,
and the blots were probed with anti-PrP 3F4 antibody.
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product of PMCA reaction performed on PI-PLC treated samples,
again in contrast to the presence of large quantities of such mate-
rial in samples containing PrPC with the native GPI anchor. Next we
performed three more rounds of serial PMCA, mixing in each round
fresh PI-PLC-treated NBH with a small aliquot (1:10 ratio) of the
product of the previous round reaction. Also in this case, we failed
to detect any ampliﬁcation of PrPres in samples containing delipi-
dated PrPC, in contrast to robust serial ampliﬁcation observed
using native (i.e., PI-PLC untreated) brain homogenate as a sub-
strate (Fig. 3C). Altogether, these data clearly demonstrate that
the GPI anchor plays an important role in PrP conversion in vitro,
and that the removal of this anchor by PI-PLC treatment greatly
diminishes – if not completely eliminates – the ability of PrPC to
act as a substrate for ampliﬁcation of PrPSc conformation by a stan-
dard PMCA procedure.4. Discussion
PMCA, a procedure that allows essentially indeﬁnite ampliﬁca-
tion of PrPres and TSE infectivity in vitro using PrPC present in nor-
mal brain homogenate as a substrate, has emerged as a powerful
tool in prion research [7–9]. The molecular mechanism of this
ampliﬁcation reaction remains, however, largely unexplored. Fur-
thermore, there is major interest in expanding this approach to
the rPrP, both from the perspective of prion diagnostics as well
as fundamental studies of the PrPC? PrPSc conversion mechanism
[19].
Here we report that, under the conditions of the standard PMCA
protocol, bacterially-expressed rPrP is a very poor substrate for
ampliﬁcation of PrPres from scrapie-infected hamsters. Further-
more, we found that, when added to NBH, rPrP acts as an efﬁcient
inhibitor of the PMCA conversion of brain PrPC. Building on these
observations, we tested the role of PrPC GPI anchor, ﬁnding that re-
moval of this anchor by PI-PLC treatment renders PrPC incompe-
tent to act as a substrate for the ampliﬁcation of PrPres by the
standard PMCA protocol.
The ﬁnding that native GPI anchor is important for the ampliﬁ-
cation of PrPres conformation in vitro by the PMCA protocol is
unexpected, especially since previous studies have shown that
both GPI-free PrPC derived from mammalian cell culture [4,20] as
well as bacterially-expressed rPrP [21] can be converted to PrPres
in a ‘‘discontinuous” cell-free conversion assay developed by Caug-
hey and coworkers [4,22]. However, the ﬁndings of those previous
cell-free conversion studies and our present PMCA experiments are
not necessarily contradictory as – despite an apparent similarity –
the assays used in these two types of studies probe distinct phe-
nomena. Thus, in PMCA experiments a minute quantity of PrPSc
is used as a seed, and essentially an inﬁnite number of substrate
PrPC molecules is converted to PrPres conformation that appears
to faithfully replicate that of the PrPSc template, with the newly
generated material being infectious [7]. This implies that, upon
binding to the surface of PrPSc seed, each molecule of the substrate
protein acquires catalytic properties of the seed, acting as a new
template for the conversion of additional substrate molecules. By
contrast, the reactions in discontinuous cell-free conversion assays
are characterized by very low yields and appear to lack any auto-
catalytic properties, with the number of PrPC molecules converted
to PrPres being substantially lower compared to input PrPSc [4,22].
Given these substoichiometric yields, it is likely that in these reac-
tions only single substrate molecule can be recruited and con-
verted to PrPres state by each catalytic site of PrPSc oligomers,
effectively ‘capping’ these sites and preventing the conversion of
additional substrates. While PrP molecules converted in this reac-
tion acquire seed-like PK-resistance, their three-dimensional struc-ture might be not identical to that of PrPSc. This would explain both
the lack of autocatalytic properties of this reaction as well as an
apparent lack of infectivity of the newly converted material [5].
The capping mechanism described above may also be operational
in our PMCA experiments using rPrP as a substrate, accounting
for the observed inhibitory effect of the latter protein on the forma-
tion of PrPres from brain-derived PrPC.
It should be noted that a modiﬁed PMCA protocol has been re-
cently developed in which the original PMCA buffer (containing
Triton X-100 as a sole detergent) was supplemented with an acidic
detergent, SDS [19]. Using this modiﬁed PMCA method, it is possi-
ble to convert, in an autocatalytic fashion, bacterially-expressed
rPrP to ﬁbrils apparently displaying PrPSc-like PK-digestion pattern
(with a 16–17 kDa PK-resistant fragment similar to that observed
for nonglycosylated PrPSc). However, this scrapie-like PK-resis-
tance persists only if PK-digestion is performed in the presence
of speciﬁc detergents used in the PMCA buffer (especially SDS),
whereas upon removal of the detergents from already converted
material the size of the longest PK-resistant fragment is reduced
to 12 kDa [12]. Thus, while this modiﬁed PMCA protocol allows
efﬁcient, PrPSc-seeded conversion of rPrP, the major structure
propagating in this reaction does not fully match that of the PrPSc
seed.
The present ﬁndings in the cell-free environment seem to echo
previous observations that the absence of the GPI moiety in PrPC
diminishes propagation of PrPSc in cell culture models of prion
infectivity [23,24]. However, the GPI anchor is not obligatory for
prion replication in vivo. This is clearly indicated by the recent
study showing that transgenic mice expressing anchorless PrP
were susceptible to infection with the scrapie agent, though these
mice did not develop clinical signs and replication of infectivity
was reduced as compared to wild-type mice [25]. In view of these
data in vivo, the apparent inability of GPI-deﬁcient PrP to support
ampliﬁcation of PrPres in PMCA reactions is highly intriguing. Our
present data suggest that the conversion reaction of the anchor-
less PrP may require speciﬁc microenvironment and/or cofactors
that are present in vivo, but are lost in homogenized samples used
in PMCA reactions. One critical factor in this regard may be the
interactions of the protein (via the anchor or directly) with biolog-
ical membranes. In the case of GPI-containing PrP, these surface
interactions (occurring largely through the anchor) are likely to
be partially preserved even upon tissue homogenization in the
presence of Triton X-100 micelles, allowing for highly efﬁcient
PrPres ampliﬁcation by PMCA. In the absence of the GPI anchor,
however, nonspeciﬁc surface interactions are likely to be compro-
mised much more readily. It appears that in the latter case, these
interactions and a conversion-conducive environment can be
mimicked to a certain degree in vitro only in the presence of
acidic detergents such as SDS, consistent with a highly basic char-
acter of the PrP.
The present ﬁndings are also relevant to understanding the ori-
gin of prion infectivity in body ﬂuids such as urine and amniotic
ﬂuid [26]. Recent data indicate that PrP present in these ﬂuids is
both N-terminally truncated as well as deﬁcient in the GPI anchor
(Notari, Gambetti, Chen, unpublished data). Our ﬁnding that, at
least under certain conditions, PrP lacking the native GPI anchor
is a poor substrate for PrPres ampliﬁcation suggests that PrPSc asso-
ciated with prion infectivity detected in urine [27] may be derived
from other sources than the delipidated PrP normally present in
this body ﬂuid.
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